title: Protease Inhibitors Do Not Affect Antibody Responses to Pneumococcal Vaccination.
abstract: HIV(+) subjects on optimal antiretroviral therapy have persistently impaired antibody responses to pneumococcal vaccination. We explored the possibility that this effect may be due to HIV protease inhibitors (PIs). We found that in humans and mice, PIs do not affect antibody production in response to pneumococcal vaccination.
authors.affiliation: Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
authors.forename: Indhira
authors.initials: I
authors.lastname: De La Rosa
authors.affiliation: Albert Einstein College of Medicine, Bronx, New York, USA.
authors.forename: Iona M
authors.initials: IM
authors.lastname: Munjal
authors.affiliation: Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.|Center for Translational Research on Inflammatory Diseases and Section of Infectious Diseases, Michael E. DeBakey VA Medical Center, Houston, Texas, USA.
authors.forename: Maria
authors.initials: M
authors.lastname: Rodriguez-Barradas
authors.affiliation: Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Yu
authors.affiliation: Albert Einstein College of Medicine, Bronx, New York, USA.
authors.forename: Liise-Anne
authors.initials: LA
authors.lastname: Pirofski
authors.affiliation: Department of Medicine, Baylor College of Medicine, Houston, Texas, USA Daniel.Mendoza@bcm.edu.|Center for Translational Research on Inflammatory Diseases and Section of Infectious Diseases, Michael E. DeBakey VA Medical Center, Houston, Texas, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Mendoza
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000097:blood; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D008297:Male; D051379:Mice; D011008:Pneumococcal Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D019438:Ritonavir / Q000627:therapeutic use; D013296:Streptococcus pneumoniae / Q000276:immunology*; D014611:Vaccination
chemical_list: D000907:Antibodies, Bacterial; D017320:HIV Protease Inhibitors; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D022242:Pneumococcal Vaccines; D019438:Ritonavir